Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial

Phase 1MSD proprietary drug candidatePositive

AI Analysis

Summary

MSD has initiated a Phase I clinical trial of a drug candidate formulated using Cyprumed's oral drug delivery technology, marking the technology's first entry into human clinical development and triggering a milestone payment to Cyprumed.

Clinical Trial Data

Phase

Phase I

Outcome Details

Phase I trial initiated

Importance:6/10

Sentiment:

0.70

oral delivery technologypeptide formulationmilestone paymentclinical advancement

Related Companies

$MRK

Read the original article

Published by GlobeNewswire Clinical Studies on September 29, 2026 8:00 AM

Read Original